I'm LongbridgeAI, I can summarize articles.Needham analyst Serge Belanger maintains a Buy rating on Liquidia Technologies with an $110 price target, citing Yutrepia's strong commercial trajectory. Q2 2026 revenue beat consensus due to market share gains in PAH and PH-ILD treatments. Supported by improved launch metrics and a larger sales force, Yutrepia is projected to reach at least $1B in annual sales by 2027 and potentially $2.5B at peak. While patent litigation poses a risk, the favorable risk-reward profile supports the positive outlook.
Serge Belanger, an analyst from Needham, maintained the Buy rating on Liquidia Technologies. The associated price target is $110.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Serge Belanger has given his Buy rating due to a combination of factors tied to Yutrepia’s strong commercial trajectory and Liquidia’s broader pipeline. Yutrepia delivered second-quarter 2026 revenue modestly ahead of consensus, driven by meaningful share gains as it increasingly becomes the standard treatment in PAH and PH-ILD, supported by new patient starts and conversions from competing inhaled, oral and parenteral therapies.
Belanger also highlights improved launch metrics and a larger sales organization as reinforcing confidence in sustained growth, underpinning expectations for Yutrepia to reach at least $1B in annual sales by 2027 and potentially $2.5B at peak in PAH/PH-ILD. He further views Yutrepia’s opportunity in adjacent lung indications and the L606 program as not fully reflected in the stock, while acknowledging ongoing patent litigation as a risk but not enough to offset the overall favorable risk-reward profile that supports a Buy recommendation.